327 reports of this reaction
1.4% of all LIOTHYRONINE SODIUM reports
#20 most reported adverse reaction
FIBROMYALGIA is the #20 most commonly reported adverse reaction for LIOTHYRONINE SODIUM, manufactured by Pfizer Laboratories Div Pfizer Inc. There are 327 FDA adverse event reports linking LIOTHYRONINE SODIUM to FIBROMYALGIA. This represents approximately 1.4% of all 23,445 adverse event reports for this drug.
Patients taking LIOTHYRONINE SODIUM who experience fibromyalgia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FIBROMYALGIA is a less commonly reported adverse event for LIOTHYRONINE SODIUM, but still significant enough to appear in the safety profile.
In addition to fibromyalgia, the following adverse reactions have been reported for LIOTHYRONINE SODIUM:
The following drugs have also been linked to fibromyalgia in FDA adverse event reports:
FIBROMYALGIA has been reported as an adverse event in 327 FDA reports for LIOTHYRONINE SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
FIBROMYALGIA accounts for approximately 1.4% of all adverse event reports for LIOTHYRONINE SODIUM, making it a notable side effect.
If you experience fibromyalgia while taking LIOTHYRONINE SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.